14 March 2025 is National Cancer Clinical Nurse Specialist (CNS) Day!
To celebrate, we spoke to Gloria, clinical nurse specialist in children, teenager and young adult genomic medicine.
Supporting cancer patients and their families as a nurse for over a decade has been a journey filled with challenges and triumphs. I have experienced joyful, lively, and reflective days that have greatly influenced my approach to life. While this work is deeply fulfilling, I also recognise the difficult moments that come with it.
"For example, I might collaborate with a multidisciplinary team, in person or remotely, so that any young patient under the age of 25 suspected of having cancer has access to whole genome sequencing as part of their diagnostic process.
"I may also network to raise awareness and help integrate the service, working on pathways and supporting new colleagues in developing this innovative genomic service. Additionally, I have opportunities for direct patient interaction, providing support and obtaining consent from patients and their families for the procedure."
Whole genome sequencing
Whole genome sequencing (WGS) refers to DNA sequencing of the entire genome to tailor treatment and care to the individual patient.
Gloria works with teenage and young adult patients, and whole genome sequencing has led to changes in diagnosis, resulting in alterations to their treatment plans and eligibility for research studies or access to existing clinical trials.
"Whole genome sequencing is geared to become a standard test in cancer diagnosis. It will provide comprehensive genome profiling with minimal turnaround time. Consequently, it will empower clinicians to make more informed decisions, to significantly enhance the overall management and outcomes for patients.
"This advancement will streamline the diagnostic process and facilitate personalised patient care.
One example of WGS impacting patient care significantly was that of Oliver.
A baby who was born with a large tumour on his leg was spared chemotherapy and surgery, after whole genome sequencing at our hospitals revealed the lump was harmless.
Gloria reflected on this, saying: " This avoided unnecessary tests and treatments, alleviated parental anxiety, and resulted in cost savings for the NHS. Remarkably, the mass regressed spontaneously about five months after his birth."
I find it reassuring that access to comprehensive whole genome sequencing tests for patients suspected of having cancer helps with accurate diagnosis. These tests also offer personalised medicine and explore how individual genetic makeup and health risks affect drug responses. I take pride in being part of a team dedicated to improving cancer outcomes for patients and their families.